Rapid PEP to PrEP Increased PrEP Uptake — But the Cost of Long-Acting Cabotegravir Remains Concerning

A U.K. report showed better uptake of preexposure prophylaxis if offered after postexposure prophylaxis, while a U.S. report concluded injectable cabotegravir for PrEP is not cost-effective at current pricing.

Despite the proven efficacy of preexposure prophylaxis (PrEP) for preventing HIV infection, its uptake has been disappointing, especially in the highest-risk populations. Two recent studies examined different strategies for improving utilization. In the first report, researchers in London reviewed their experience with the strategy of rapid-start “opt-out” PrEP for persons prescribed postexposure prophylaxis (PEP). In their comparison of patients being seen for PEP during the time periods before and after the introduction of opt-out PrEP, rates of PrEP dispensing increased significantly from 17.5% (10 of 57 eligible recipients) to 53.1% (17 of 32). This PrEP strategy was generally well accepted by patients.

The second study was a cost-benefi…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Rapid PEP to PrEP Increased PrEP Uptake — But the Cost of Long-Acting Cabotegravir Remains Concerning

Topics

Reviewing Author